clofibric acid has been researched along with Liver Dysfunction in 6 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Myositis was significantly associated with statin monotherapy (RR 2." | 1.34 | Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. ( Glanz, M; Hokanson, JE; McClure, DL; Murphy, JR; Valuck, RJ, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suzuki, A | 1 |
| Yuen, N | 1 |
| Walsh, J | 1 |
| Papay, J | 1 |
| Hunt, CM | 1 |
| Diehl, AM | 1 |
| Elfaki, DA | 1 |
| Bjornsson, E | 1 |
| Lindor, KD | 1 |
| Wierzbicki, AS | 1 |
| Mikhailidis, DP | 2 |
| Wray, R | 1 |
| McClure, DL | 1 |
| Valuck, RJ | 1 |
| Glanz, M | 1 |
| Murphy, JR | 1 |
| Hokanson, JE | 1 |
| Florentin, M | 1 |
| Liberopoulos, EN | 1 |
| Elisaf, MS | 1 |
| Perault, MC | 1 |
| Fievre, JL | 1 |
| Dejean, C | 1 |
| Martin, A | 1 |
| Vandel, B | 1 |
3 reviews available for clofibric acid and Liver Dysfunction
| Article | Year |
|---|---|
Review article: nuclear receptors and liver disease--current understanding and new therapeutic implications.
Topics: Clofibric Acid; Humans; Ligands; Liver Diseases; Receptors, Cytoplasmic and Nuclear; Thiazolidinedio | 2009 |
Drug treatment of combined hyperlipidemia.
Topics: Acute Disease; Clofibric Acid; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydroxymethyl | 2001 |
Fibrate-associated adverse effects beyond muscle and liver toxicity.
Topics: Animals; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Clofibric Acid; Humans; L | 2008 |
3 other studies available for clofibric acid and Liver Dysfunction
| Article | Year |
|---|---|
Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury.
Topics: Acetaminophen; Adrenergic Agonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensi | 2009 |
Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population.
Topics: Age Factors; Aged; Clofibric Acid; Cohort Studies; Confidence Intervals; Confounding Factors, Epidem | 2007 |
[Cytolytic hepatic damage caused by ciprofibrate].
Topics: Aged; Chemical and Drug Induced Liver Injury; Clofibric Acid; Female; Fibric Acids; Humans; Hypercho | 1992 |